ADA: Insulin Efsitora Noninferior to Glargine for Reducing HbA1c in Adults With Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
FRIDAY, June 27, 2025 -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among adults with type 2 diabetes, according to a study published online June 25 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.
Julio Rosenstock, M.D., from Velocity Clinical Research at Medical City in Dallas, and colleagues conducted a 52-week, phase 3 trial involving adults with type 2 diabetes who had not previously received insulin. A total of 795 participants were randomly assigned to receive once-weekly efsitora, initiated at 100 U, with dose adjustments made every four weeks as needed, or once-daily insulin glargine, with doses adjusted weekly or more often to reach the same glycemic goals.
The researchers observed a decrease in mean HbA1c from baseline to week 52 from 8.20 to 7.05 percent with efsitora and from 8.28 to 7.08 percent with glargine (least-squares mean change, −1.19 and −1.16 percentage points, respectively), confirming the noninferiority of efsitora to glargine. Superiority was not achieved (P = 0.68). The rate of combined clinically significant hypoglycemia or severe hypoglycemia was lower with efsitora than glargine (0.50 versus 0.88 events per participant-year of exposure; estimated rate ratio, 0.57). The mean total weekly insulin dose was 289.1 and 332.8 U/week with efsitora and glargine, respectively, at week 52.
"Once-weekly efsitora administered in a fixed-dose regimen was noninferior to once-daily glargine in reducing glycated hemoglobin levels at 52 weeks," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which is developing efsitora and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial...
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.